Sujiet Puthenveetil
Director- Antibody Drug Conjugates & Radioconjugates AstraZeneca
Dr. Sujiet Puthenveetil is a Director of Antibody-Drug Conjugates (ADCs) and Radioconjugates at AstraZeneca, where he leads the development of next-generation cancer therapeutics. With over a decade of specialized experience, his career includes key scientific roles at AbbVie and Pfizer, where he pioneered high-throughput conjugation methodologies and novel payload-linker strategies. He began his industry career advancing bioconjugation techniques and analytics for ADCs. Dr. Puthenveetil completed his postdoctoral training in protein engineering at MIT and holds a Ph.D. in Chemical Biology from the University of Utah. His expertise bridges chemistry and biology to drive innovation in targeted therapeutics.
Seminars
The future of antibody-drug conjugates is accelerating beyond traditional cytotoxic payloads, fueled by rapid innovation in linker engineering, novel conjugation platforms, and the integration of computational biology. As converging technologies redefine what an ADC can deliver, the antibody is evolving into a versatile delivery vehicle capable of transporting an increasingly diverse therapeutic arsenal.
This session explores the feasibility and promise of emerging payload classes, the transformation of the linker from a
passive connector into an active, programmable controller of drug release, and strategies for designing molecules that are translatable and manufacturable from day one.
Join this panel to gain strategic foresight on positioning your ADC programs at the forefront of targeted oncology and beyond by discussing:
- Exploring the transition beyond cytotoxins to integrate degraders, radio nuclides, and immune modulators, focusing on the radical linker and conjugation innovations required to expand the ADC therapeutic arsenal into new disease spaces
- Debating the future role of the linker as a smart, stimuli-responsive "payload traffic controller", evaluating emerging technologies to achieve maximal tumor killing with minimal systemic exposure for an optimized therapeutic window
- Strategizing to build future-proof platforms that integrate predictive in silico modelling of biophysical properties with scalable site-specific conjugation, to de-risk development timelines and accelerate the delivery of next-generation ADCs to patients
